Payer+Provider's Health System Review
An update on prostate cancer treatment [PODCAST]
FDA Weighs Approval of a Lucrative Alzheimer’s Drug but Benefits Are Iffy
June 3, 2021
The health plans contend they lost their ability to improve their star ratings due to the CMS interim final rule.
Read the full post on News Feed